Carregant...
Whether, when, how, and how much? General public’s and cancer patients’ views about the disclosure of genomic secondary findings
BACKGROUND: Data on the modalities of disclosing genomic secondary findings (SFs) remain scarce. We explore cancer patients’ and the general public’s perspectives about disclosing genomic SFs and the modalities of such disclosure. METHODS: Sixty-one cancer patients (n = 29) and members of the public...
Guardat en:
| Publicat a: | BMC Med Genomics |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8236159/ https://ncbi.nlm.nih.gov/pubmed/34174888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-021-01016-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|